Effect of Psychotropic Drug Treatment on Sterol Metabolism

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2017 Feb 17

PMID 28202290

Citations 27

Authors

Zeljka Korade

Wei Liu

Emily B Warren

Kristan Armstrong

Ned A Porter

Christine Konradi

Affiliations

Soon will be listed here.

Abstract

Cholesterol metabolism is vital for brain function. Previous work in cultured cells has shown that a number of psychotropic drugs inhibit the activity of 7-dehydrocholesterol reductase (DHCR7), an enzyme that catalyzes the final steps in cholesterol biosynthesis. This leads to the accumulation of 7-dehydrocholesterol (7DHC), a molecule that gives rise to oxysterols, vitamin D, and atypical neurosteroids. We examined levels of cholesterol and the cholesterol precursors desmosterol, lanosterol, 7DHC and its isomer 8-dehydrocholesterol (8DHC), in blood samples of 123 psychiatric patients on various antipsychotic and antidepressant drugs, and 85 healthy controls, to see if the observations in cell lines hold true for patients as well. Three drugs, aripiprazole, haloperidol and trazodone increased circulating 7DHC and 8DHC levels, while five other drugs, clozapine, escitalopram/citalopram, lamotrigine, olanzapine, and risperidone, did not. Studies in rat brain verified that haloperidol dose-dependently increased 7DHC and 8DHC levels, while clozapine had no effect. We conclude that further studies should investigate the role of 7DHC and 8DHC metabolites, such as oxysterols, vitamin D, and atypical neurosteroids, in the deleterious and therapeutic effects of psychotropic drugs. Finally, we recommend that drugs that increase 7DHC levels should not be prescribed during pregnancy, as children born with DHCR7 deficiency have multiple congenital malformations.

Citing Articles

Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.

Villate A, Olivares M, Usobiaga A, Unzueta-Larrinaga P, Barrena-Barbadillo R, Callado L Sci Rep. 2024; 14(1):31492.

PMID: 39733019 PMC: 11682106. DOI: 10.1038/s41598-024-83288-5.

A novel syndrome associated with prenatal fentanyl exposure.

Wadman E, Fernandes E, Muss C, Powell-Hamilton N, Wojcik M, Madden J Genet Med Open. 2024; 1(1):100834.

PMID: 39669238 PMC: 11613603. DOI: 10.1016/j.gimo.2023.100834.

Embryotoxicity of statins and other prescribed drugs with reported off-target effects on cholesterol biosynthesis.

Hartley T, Abdelmagid H, Abdulsalam Z, Mansion A, Howe E, Ramirez D Reprod Toxicol. 2024; 132:108820.

PMID: 39667684 PMC: 11890968. DOI: 10.1016/j.reprotox.2024.108820.

Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS).

Korade Z, Anderson A, Sharma K, Tallman K, Kim H, Porter N Mol Psychiatry. 2024; 29(12):3942-3949.

PMID: 38844533 DOI: 10.1038/s41380-024-02622-5.

Chemical Inhibition of Sterol Biosynthesis.

Peeples E, Mirnics K, Korade Z Biomolecules. 2024; 14(4).

PMID: 38672427 PMC: 11048061. DOI: 10.3390/biom14040410.

References

Kupferberg A, Cremel G, Behr P, Van Dorsselaer A, Luu B, Mersel M . Differential sensitivity of astrocyte primary cultures and derived spontaneous transformed cell lines to 7 beta-hydroxycholesterol: effect on plasma membrane lipid composition and fluidity, and on cell surface protein expression. Mol Cell Biochem. 1991; 101(1):11-22. DOI: 10.1007/BF00238433. View

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W . Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2010; 38(1):167-77. PMC: 3245581. DOI: 10.1093/schbul/sbq042. View

Tatsuta T, Scharwey M, Langer T . Mitochondrial lipid trafficking. Trends Cell Biol. 2013; 24(1):44-52. DOI: 10.1016/j.tcb.2013.07.011. View

Nicholas H, Thomas B . Cholesterol metabolism and the blood-brain barrier: an experimental study with 2-C14-sodium acetate. Brain. 1961; 84:320-8. DOI: 10.1093/brain/84.2.320. View

Xu L, Korade Z, Rosado Jr D, Mirnics K, Porter N . Metabolism of oxysterols derived from nonenzymatic oxidation of 7-dehydrocholesterol in cells. J Lipid Res. 2013; 54(4):1135-43. PMC: 3605989. DOI: 10.1194/jlr.M035733. View

Slominski A, Li W, Kim T, Semak I, Wang J, Zjawiony J . Novel activities of CYP11A1 and their potential physiological significance. J Steroid Biochem Mol Biol. 2014; 151:25-37. PMC: 4757911. DOI: 10.1016/j.jsbmb.2014.11.010. View

Dietschy J, Turley S . Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001; 12(2):105-12. DOI: 10.1097/00041433-200104000-00003. View

Korade Z, Xu L, Harrison F, Ahsen R, Hart S, Folkes O . Antioxidant supplementation ameliorates molecular deficits in Smith-Lemli-Opitz syndrome. Biol Psychiatry. 2013; 75(3):215-22. PMC: 3874268. DOI: 10.1016/j.biopsych.2013.06.013. View

Tsai G, Goff D, Chang R, Flood J, Baer L, Coyle J . Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998; 155(9):1207-13. DOI: 10.1176/ajp.155.9.1207. View

10.

Korade Z, Xu L, Mirnics K, Porter N . Lipid biomarkers of oxidative stress in a genetic mouse model of Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2012; 36(1):113-22. PMC: 3674764. DOI: 10.1007/s10545-012-9504-z. View

11.

Marcos J, Guo L, Wilson W, Porter F, Shackleton C . The implications of 7-dehydrosterol-7-reductase deficiency (Smith-Lemli-Opitz syndrome) to neurosteroid production. Steroids. 2004; 69(1):51-60. DOI: 10.1016/j.steroids.2003.09.013. View

12.

Bernagie C, Danckaerts M, Wampers M, De Hert M . Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs. 2016; 30(9):807-18. PMC: 4996892. DOI: 10.1007/s40263-016-0367-y. View

13.

Eyles D, Smith S, Kinobe R, Hewison M, McGrath J . Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2004; 29(1):21-30. DOI: 10.1016/j.jchemneu.2004.08.006. View

14.

Saletu-Zyhlarz G, Anderer P, Arnold O, Saletu B . Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology. 2003; 48(4):194-208. DOI: 10.1159/000074638. View

15.

McGrath J, Eyles D, Pedersen C, Anderson C, Ko P, Burne T . Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry. 2010; 67(9):889-94. DOI: 10.1001/archgenpsychiatry.2010.110. View

16.

Hall P, Michels V, Gavrilov D, Matern D, Oglesbee D, Raymond K . Aripiprazole and trazodone cause elevations of 7-dehydrocholesterol in the absence of Smith-Lemli-Opitz Syndrome. Mol Genet Metab. 2013; 110(1-2):176-8. DOI: 10.1016/j.ymgme.2013.04.004. View

17.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

18.

Xu L, Davis T, Porter N . Rate constants for peroxidation of polyunsaturated fatty acids and sterols in solution and in liposomes. J Am Chem Soc. 2009; 131(36):13037-44. PMC: 3656724. DOI: 10.1021/ja9029076. View

19.

Docherty J, Baker R, Eudicone J, Mathew S, Marcus R, McQuade R . Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophr Res. 2010; 120(1-3):199-203. DOI: 10.1016/j.schres.2010.03.040. View

20.

Kahn R, Fleischhacker W, Boter H, Davidson M, Vergouwe Y, Keet I . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371(9618):1085-97. DOI: 10.1016/S0140-6736(08)60486-9. View